Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to start prophylaxis.

P Petrini1

  • 1Department of Pediatric/Coagulation Disorders, Karolinska Hospital, Stockholm, Sweden. pia.petrini@ks.se

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 24, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel on-a-chip system with a 3D-bioinspired gut mucus suitable to investigate bacterial endotoxins dynamics.

Materials today. Bio·2024
Same author

Engineering biological gradients.

Journal of applied biomaterials & functional materials·2019
Same author

Factor IX inhibitors and anaphylaxis in hemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Evaluating outcome of prophylaxis in haemophilia: objective and self-reported instruments should be combined.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed.

Haemophilia : the official journal of the World Federation of Hemophilia·2015
Same author

How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access.

Haemophilia : the official journal of the World Federation of Hemophilia·2015

Peripheral vein injections for primary prophylaxis are effective in most boys with severe hemophilia (83%). This approach, starting early, significantly reduced bleeding symptoms and prevented cerebral bleeds.

Area of Science:

  • Hematology
  • Pediatric Medicine
  • Vascular Access

Background:

  • Severe hemophilia requires early intervention to prevent debilitating bleeding.
  • Primary prophylaxis is the standard of care, but venous access can be challenging.
  • Peripheral vein injections offer a potential alternative to central venous access for prophylaxis.

Purpose of the Study:

  • To evaluate the efficacy and safety of initiating primary prophylaxis via peripheral vein injections in boys with severe hemophilia.
  • To assess bleeding symptoms before and during the transition to home-based prophylaxis.
  • To determine the feasibility of peripheral venous access for long-term hemophilia treatment.

Main Methods:

  • A cohort study of 47 boys with severe hemophilia (born 1987-2000) was conducted.

Related Experiment Videos

  • Data collected on bleeding events prior to and during prophylaxis initiation.
  • Mean age at prophylaxis start was 16 months; mean age for full prophylaxis was 30 months.

    • Main Results:

    • Primary prophylaxis via peripheral vein injections was successful in 83% of patients.
    • Despite early initiation, 59% received clotting factor concentrate before prophylaxis.
    • 72% experienced no joint or muscle bleeding during prophylaxis transition.
    • No cerebral bleeding occurred; one patient presented with epidural bleeding.

    Conclusions:

    • Gradual introduction of primary prophylaxis through peripheral vein injections is feasible and effective for most boys with severe hemophilia.
    • Early prophylaxis initiation via peripheral veins can significantly reduce bleeding complications.
    • Peripheral venous access is a viable option for home treatment in pediatric hemophilia management.